Attached files
| file | filename |
|---|---|
| 10-K - 10-K-2016 - Ocera Therapeutics, Inc. | ocera10-k2016.htm |
| EX-32.2 - EXHIBIT 32.2 - Ocera Therapeutics, Inc. | ocrxexhibit32210k2016.htm |
| EX-32.1 - EXHIBIT 32.1 - Ocera Therapeutics, Inc. | ocrxexhibit32110k2016.htm |
| EX-31.2 - EXHIBIT 31.2 - Ocera Therapeutics, Inc. | ocrxexhibit31210k2016.htm |
| EX-31.1 - EXHIBIT 31.1 - Ocera Therapeutics, Inc. | ocrxexhibit31110k2016.htm |
| EX-21.1 - EXHIBIT 21.1 - Ocera Therapeutics, Inc. | ocrxexhibit21110k2016.htm |
Exhibit 23.1 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the following Registration Statements:
1. | Registration Statement (Form S-3 No. 333-204214) of Ocera Therapeutics, Inc., |
2. | Registration Statement (Form S-8 No. 333-173535) pertaining to the 2001 Employee Stock Option Plan of Tranzyme, Inc., 2001 Non-Employee Stock Option Plan of Tranzyme, Inc., Amended and Restated 2003 Stock Option Plan of Tranzyme, Inc., Amended and Restated 2004 Stock Option Plan of Tranzyme Pharma, Inc., and the 2011 Stock Option and Incentive Plan of Tranzyme, Inc., |
3. | Registration Statement (Form S-8 No. 333-182408) pertaining to the Amended and Restated 2011 Stock Option and Incentive Plan of Tranzyme, Inc., |
4. | Registration Statement (Form S-8 No. 333-191644) pertaining to the Ocera Therapeutics, Inc. 2005 Stock Plan, |
5. | Registration Statement (Form S-8 No. 333-193094) pertaining to the Ocera Therapeutics, Inc. Second Amended and Restated 2011 Stock Option and Incentive Plan, |
6. | Registration Statement (Form S-8 No. 333-205475) pertaining to the Ocera Therapeutics, Inc. Third Amended and Restated 2011 Stock Option and Incentive Plan, and |
7. | Registration Statement (Form S-8 No. 333-212053) pertaining to the Ocera Therapeutics, Inc. Fourth Amended and Restated 2011 Stock Option and Incentive Plan, |
of our reports dated March 14, 2017, with respect to the consolidated financial statements of Ocera Therapeutics, Inc. included in this Annual Report (Form 10-K) for the year ended December 31, 2016.
/s/ Ernst & Young LLP
Redwood City, California
March 14, 2017